Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;49(9):803-9.
doi: 10.1002/gcc.20789.

Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma

Annette Schmidt  1 , Roland Schmitz, Maciej Giefing, Jose Ignacio Martin-Subero, Stefan Gesk, Inga Vater, Anne Massow, Ewerton Maggio, Markus Schneider, Martin-Leo Hansmann, Reiner Siebert, Ralf Küppers
Affiliations

Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma

Annette Schmidt et al. Genes Chromosomes Cancer. 2010 Sep.

Abstract

Survival of the malignant Hodgkin and Reed/Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) is dependent on constitutive activation of the nuclear factor kappaB (NF-kappaB) transcription factor. The deubiquitinating enzyme CYLD is a negative regulator of NF-kappaB and known to function as a tumor suppressor. To determine whether CYLD mutations play a role in cHL pathogenesis, we sequenced the gene in cHL cell lines and microdissected HRS cells obtained from lymph-node biopsies. A biallelic inactivation by mutations was found in the cHL cell-line KM-H2. However, the other seven cHL cell lines analyzed and HRS cells of 10 primary cHL cases did not show any mutations. By interphase cytogenetics, a (sub)clonal biallelic CYLD deletion was observed by interphase cytogenetics in 1 of 29 primary cHL, whereas signal patterns indicating decreased CYLD copy numbers were observed in a total of 10 of 29 primary cases. Our results suggest that biallelic CYLD mutations are rarely involved in cHL pathogenesis. Nevertheless, it is remarkable that KM-H2 cells, besides the CYLD mutations, also carry inactivating mutations in the genes of two other NF-kappaB inhibitors, that is, NFKBIA and TNFAIP3, exemplifying that multiple lesions in regulators of this signaling pathway can likely cooperatively contribute to the strong NF-kappaB activity of these cells.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Molecular biology of Hodgkin lymphoma.
    Weniger MA, Küppers R. Weniger MA, et al. Leukemia. 2021 Apr;35(4):968-981. doi: 10.1038/s41375-021-01204-6. Epub 2021 Mar 8. Leukemia. 2021. PMID: 33686198 Free PMC article. Review.
  • CYLD in health and disease.
    Marín-Rubio JL, Raote I, Inns J, Dobson-Stone C, Rajan N. Marín-Rubio JL, et al. Dis Model Mech. 2023 Jun 1;16(6):dmm050093. doi: 10.1242/dmm.050093. Epub 2023 Jun 30. Dis Model Mech. 2023. PMID: 37387450 Free PMC article. Review.
  • NFkB Pathway and Hodgkin Lymphoma.
    Jardin F. Jardin F. Biomedicines. 2022 Sep 1;10(9):2153. doi: 10.3390/biomedicines10092153. Biomedicines. 2022. PMID: 36140254 Free PMC article. Review.
  • Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma.
    Nagel S, Meyer C, Kaufmann M, Drexler HG, MacLeod RA. Nagel S, et al. Oncotarget. 2015 Nov 24;6(37):40112-26. doi: 10.18632/oncotarget.5556. Oncotarget. 2015. PMID: 26473286 Free PMC article.
  • Genetic Testing in CYLD Cutaneous Syndrome: An Update.
    Nagy N, Dubois A, Szell M, Rajan N. Nagy N, et al. Appl Clin Genet. 2021 Oct 29;14:427-444. doi: 10.2147/TACG.S288274. eCollection 2021. Appl Clin Genet. 2021. PMID: 34744449 Free PMC article. Review.
See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources